Restricted accessLetterFirst published online 2024-6
Newer treatments for diabetes mellitus: A caveat with rapid glycaemic improvement and caution regarding changes in retinopathy screening guidelines within the UK NHS programme
VarugheseGIJacobS.Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening. J R Coll Physicians Edinb. Epub ahead of Print 05 April 2024. DOI: 10.1177/14782715241244843
2.
VaradhanLHumphreysTHarimanC, et al. GLP-1 agonist treatment: implications for diabetic retinopathy screening. Diabetes Res Clin Pract2011; 94: 68.
3.
MarsoSPBainSCConsoliA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med2016; 375: 1834–1844.
4.
SabanayagamCBanuRCheeML, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol2019; 7: 140–149.
5.
JacobSVarugheseGI.Enhancing glycaemic control with impetus on weight management: Observing for early worsening of diabetic retinopathy. Eye (Lond) Epub ahead of Print 10 February 2024. DOI: 10.1038/s41433-024-02980-y
6.
FriasJPDaviesMJRosenstockJ, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med2021; 385: 503–515.
